ABSTRACT
Tamoxifen (TAM) is currently the endocrine treatment of choice for all stages of breast cancer; it has proven success in ER positive and ER negative patients. TAM is activated by endogenous CYP450 enzymes to the more biologically active metabolites 4-hydroxytamoxifen and endoxifen mainly via CYP2D6 and CYP3A4/5. CYP2D6 has been investigated for polymorphism; there is a large interindividual variation in the enzyme activity, this drastically effects clinical outcomes of tamoxifen treatment. Here in we report the design and synthesis of 10 novel compounds bearing a modified tamoxifen skeleton, ring C is substituted with different ester groups to bypass the CYP2D6 enzyme metabolism and employ esterase enzymes for activation. All compounds endorse flexibility on ring A. Compounds (II-X) showed MCF-7% growth inhibition >50% at a screening dose of 10 µM. These results were validated by yeast estrogen screen (YES) and E-Screen assay combined with XTT assay. Compound II (E/Z 4-[1-4-(3-Dimethylamino-propoxy)-phenyl)-3-(4-methoxy-phenyl)-2-methyl-propenyl]-phenol) showed nanomolar antiestrogenic activity (IC50 = 510 nM in YES assay) and was five times more potent in inhibiting the growth of MCF-7 BUS (IC50 = 96 nM) compared to TAM (IC50 = 503 nM). Esterified analogues VI, VII were three times more active than TAM on MCF-7 BUS (IC50 = 167 nM). Novel analogues are prodrugs that can ensure equal clinical outcomes to all breast cancer patients.
Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/drug therapy , Cytochrome P-450 CYP2D6/genetics , Tamoxifen/pharmacology , Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/chemistry , Female , Humans , Inhibitory Concentration 50 , MCF-7 Cells , Polymorphism, Genetic , Structure-Activity Relationship , Tamoxifen/analogs & derivatives , Tamoxifen/chemical synthesisABSTRACT
The direct carbolithiation of diphenylacetylenes and their cross-coupling procedure taking advantage of the intermediate alkenyllithium reagents are presented. By employing our recently discovered highly active palladium nanoparticle based catalyst, we were able to couple an alkenyllithium reagent with a high (Z/E) selectivity (10 : 1) and good yield to give the breast cancer drug tamoxifen in just 2 steps from commercially available starting materials and with excellent atom economy and reaction mass efficiency.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Estrogen Antagonists/chemical synthesis , Tamoxifen/chemical synthesis , Acetylene/analogs & derivatives , Acetylene/chemical synthesis , Acetylene/chemistry , Catalysis , Indicators and Reagents , Lithium/chemistry , Metal Nanoparticles/chemistry , Palladium/chemistryABSTRACT
A series of 2,3,4-triaryl-substituted 1,2,4-oxadiazole-5-ones have been prepared as fixed-ring analogues of tamoxifen (TAM), a drug inhibitor of Estradiol Receptor (ER) used in breast cancer therapy, by an efficient synthetic protocol based on a 1,3-dipolar cycloaddition of nitrones to isocyanates. Some of the newly synthesized compounds (14d-f, 14h and 14k) show a significant cytotoxic effect in a human breast cancer cell line (MCF-7) possessing IC50 values between 15.63 and 31.82 µM. In addition, compounds 14d-f, 14h and 14k are able to increase the p53 expression levels, activating also the apoptotic pathway. Molecular modeling studies of novel compounds performed on the crystal structure of ER reveal the presence of strong hydrophobic interactions with the aromatic rings of the ligands similar to TAM. These data suggest that 1,2,4-oxadiazole-5-ones can be considered analogues of TAM, and that their anticancer activity might be partially due to ER inhibition.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/pharmacology , Oxadiazoles/chemical synthesis , Oxadiazoles/pharmacology , Tamoxifen/analogs & derivatives , Antineoplastic Agents, Hormonal/chemistry , Cell Proliferation/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Female , Humans , Hydrophobic and Hydrophilic Interactions , MCF-7 Cells , Molecular Structure , Oxadiazoles/chemistry , Quantum Theory , Structure-Activity Relationship , Tamoxifen/chemistry , Tumor Cells, CulturedABSTRACT
Nomegestrol acetate (NOMAc) is a synthetic progesterone analog and classified as a fourth-generation progestin. It has been approved in many countries for oral contraception, hormonal replacement therapy (HRT), and treatment of various gynecological disorders. There are several synthetic routes reported for the synthesis of NOMAc and they all share the very similar last three to five steps toward the conversion of 6-methylene to 6-methyl-6,7-unsaturated structure. Therefore the final product from different processing routes may have similar impurity profiles. In the analysis of NOMAc, we identified two impurities, impurity A (listed in EP 8.0) and impurity B (not specified in EP 8.0). Both impurities were further confirmed by synthesis. In addition, both impurities and NOMAc were evaluated for their in vitro cytotoxicities against L02 liver cells, mesenchymal stem cells, MCF-7 breast cancer cells, and C33A cervical cancer cells. These three analogs are not cytotoxic to the four cell lines at low concentrations (<20 µM). NOMAc and impurity A showed cytotoxicity to L02, MCF-7, and C33A cells at high concentrations, while impurity B did not show significant cytotoxicity to any of the cell lines tested.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Drug Discovery/methods , Megestrol/chemical synthesis , Norpregnadienes/chemical synthesis , Progesterone Congeners/chemical synthesis , Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Drug Contamination , Humans , Megestrol/chemistry , Megestrol/pharmacology , Molecular Structure , Norpregnadienes/chemistry , Norpregnadienes/pharmacology , Progesterone Congeners/chemistry , Progesterone Congeners/pharmacologyABSTRACT
A series of estrone derivatives 3â»8 was designed and synthesized using estrone arylmethylenes 2a,b as starting materials and their structures were confirmed by different spectral data and elemental analyses. All the newly synthesized compounds exhibited potent in vitro and in vivo cytotoxic activities against breast cancer cell lines. In addition, all compounds were subjected to in vitro and in vivo inhibition assays for EGFR and VEGFR-2 kinases as well as p53 ubiquitination activity to obtain more details about their mechanism of action. Based on the promising results, a molecular docking study was investigated for the most representative compound 5a against the two targets, EGFR and VEGFR-2 kinases, to assess its binding affinity, hoping to rationalize and obtain potent anticancer agents in the future.
Subject(s)
Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Drug Design , Estrogens/chemistry , Estrogens/pharmacology , Models, Molecular , Animals , Antineoplastic Agents, Hormonal/chemical synthesis , Binding Sites , Cell Line, Tumor , Cell Proliferation/drug effects , Chemistry Techniques, Synthetic , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Estrogens/analogs & derivatives , Estrogens/chemical synthesis , Female , Humans , Inhibitory Concentration 50 , Mice , Molecular Structure , Protein Binding , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Quantitative Structure-Activity Relationship , Tumor Suppressor Protein p53/metabolism , Ubiquitination/drug effects , Xenograft Model Antitumor AssaysABSTRACT
Z-Endoxifen is widely regarded as the most active metabolite of tamoxifen, and has recently demonstrated a 26.3% clinical benefit in a phase I clinical trial to treat metastatic breast cancer after the failure of standard endocrine therapy. Future pharmacological and pre-clinical studies of Z-endoxifen would benefit from reliable and efficient synthetic access to the drug. Here, we describe a short and efficient, stereoselective synthesis of Z-endoxifen capable of delivering multi-gram (37â¯g) quantities of the drug inâ¯>97% purity with a Z/E ratioâ¯>99% after trituration.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Tamoxifen/analogs & derivatives , Antineoplastic Agents, Hormonal/chemistry , Stereoisomerism , Tamoxifen/chemical synthesis , Tamoxifen/chemistryABSTRACT
Hormone based drug targeting is a promising tool for selective tumor therapy. In this study, synthesis and systematic comparative biological evaluation of novel drug containing analogs of gonadotropin-releasing hormone GnRH-I and GnRH-II is reported demonstrating their suitability for tumor targeting. The cytotoxic conjugates were prepared by the attachment of the chemotherapeutical agent daunorubicin (Dau) to GnRH analogs directly or through an enzyme-labile spacer with oxime linkage. All conjugates were found to be proteolytically stable under circumstances applied in biological assays. Both GnRH-I and GnRH-II were able to bind similarly to high-affinity GnRH-I receptors on human pituitary and human prostate cancer cells. The in vitro long-term cytotoxic effect of the conjugates was comparable with that of the free drug in human breast and colon cancer cell lines. Furthermore, a concentration-dependent cellular uptake profile was observed. The in vitro apoptotic effect of the compounds was evaluated by flow cytometry analysis using annexin-V. Our results show that both the GnRH-I and the GnRH-II based analogs might be applied for targeted tumor therapy.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/pharmacology , Daunorubicin/chemistry , Gonadotropin-Releasing Hormone/analogs & derivatives , Antineoplastic Agents, Hormonal/therapeutic use , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Daunorubicin/pharmacology , Gonadotropin-Releasing Hormone/chemistry , HT29 Cells , Humans , MCF-7 Cells , Male , Pituitary Neoplasms/drug therapy , Pituitary Neoplasms/metabolism , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/metabolism , Receptors, LHRH/metabolismABSTRACT
The role of progesterone in women's cancers as well as the knowledge of the progesterone receptor (PR) structure has prompted the design of different therapies. The aim of this review is to describe the basic structure of PR agonists and antagonists as well as the recent treatments for illness associated with the progesterone receptor. The rational design for potent and effective drugs for the treatment of female cancer must consider the structural changes of the androgen and progestogen skeleton which are an indicator of their activity as progestins or antiprogestins. The presence of a hydroxyl group at C-17 in the progesterone skeleton brings about a loss of progestational activity whereas acetylation induces a progestational effect. The incorporation of an ethynyl functional group to the testosterone framework results in a loss of androgenic activity with a concomitant enhancement of the progestational effect. On the other hand, an ester function at C-3 of dehydroepiandrosterone skeleton induces partial antagonism to the PR.
Subject(s)
Antineoplastic Agents, Hormonal/chemistry , Breast Neoplasms/drug therapy , Progestins/chemistry , Receptors, Progesterone/agonists , Receptors, Progesterone/antagonists & inhibitors , Acetylation , Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/pharmacology , Binding Sites , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Dehydroepiandrosterone/chemistry , Drug Design , Female , Humans , Hydroxylation , Progesterone/chemistry , Progestins/chemical synthesis , Progestins/pharmacology , Protein Binding , Receptors, Progesterone/metabolism , Structure-Activity Relationship , Testosterone/chemistryABSTRACT
We first report the application of 3-acyl-5-hydroxybenzofurans as a scaffold to develop potential drugs for breast cancer. Seven novel derivative compounds were synthesized by using a microwave-assisted synthesis method. Those compounds exhibited different antiproliferation against human breast cancer MCF-7 cells, with the best activity of IC50=43.08µM for compound 1. A Quantum Mechanics Polarized Ligand Docking (QPLD) study was carried out to investigate the binding interactions between these compounds and estrogen receptor alpha (ERα). The simulation results showed that the trend of receptor-ligand binding interactions was same as that of their antiproliferative activities. A detailed analysis indicated that compound 1 possesses the highest Van der Waals and hydrogen bond interactions compared to the other six compounds and better inhibitors are achievable by enhancing the hydrogen bond interactions. Based on these results, we addressed that 3-acyl-5-hydroxybenzofuran is an attractive scaffold for designing drugs against breast cancer.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Benzofurans/chemical synthesis , Breast Neoplasms/drug therapy , Quantum Theory , Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Benzofurans/chemistry , Benzofurans/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Estrogen Receptor alpha/metabolism , Female , Humans , Hydroxylation , MCF-7 Cells , Molecular StructureABSTRACT
The design and synthesis of 11 fluorinated derivatives of tamoxifen are described. Growth inhibition values (GI50) on human HT-29, M21, MCF7, and MDA-MB-231 tumor cells are also reported. In general, the GI50 values are similar or slightly higher than tamoxifen with the most active compound on MCF7 cell line having a GI50=3.6µM. Surprisingly, as opposed to tamoxifen, both geometrical isomers behave similarly. We hypothesize that this behavior is due to in vitro isomerization of the compounds.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Tamoxifen/analogs & derivatives , Alkenes/chemistry , Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/toxicity , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , HT29 Cells , Halogenation , Humans , MCF-7 Cells , Stereoisomerism , Tamoxifen/chemical synthesis , Tamoxifen/toxicityABSTRACT
We synthesized two series of androstane derivatives as inhibitors of type 3 and type 5 17ß-hydroxysteroid dehydrogenases (17ß-HSDs). In the first series, four monospiro derivatives at position C17 were prepared from androsterone (ADT) or epi-ADT. After the protection of the alcohol at C3, the C17-ketone was alkylated with the lithium acetylide of tetrahydro-2-(but-3-ynyl)-2-H-pyran, the triple bond was hydrogenated, the protecting groups hydrolysed and the alcohols oxidized to give the corresponding 3-keto-17-spiro-lactone derivative. The other three compounds were generated from this keto-lactone by reducing the ketone at C3, or by introducing one or two methyl groups. In the second series, two dispiro derivatives at C3 and C17 were prepared from epi-ADT. After introducing a spiro-δ-lactone at C17 and an oxirane at C3, an aminolysis of the oxirane with L-isoleucine methyl ester provided an amino alcohol, which was treated with triphosgene or sodium methylate to afford a carbamate- or a morpholinone-androstane derivative, respectively. These steroid derivatives inhibited 17ß-HSD3 (14-88% at 1 µM; 46-94% at 10 µM) and 17ß-HSD5 (54-73% at 0.3 µM; 91-92% at 3 µM). They did not produce any androgenic activity and did not bind steroid (androgen, estrogen, glucocorticoid and progestin) receptors, suggesting a good profile for prostate cancer therapy.
Subject(s)
17-Hydroxysteroid Dehydrogenases/antagonists & inhibitors , Androstanes/chemical synthesis , Antineoplastic Agents, Hormonal/chemical synthesis , 17-Hydroxysteroid Dehydrogenases/biosynthesis , Androstanes/pharmacology , Antineoplastic Agents, Hormonal/pharmacology , Carbamates/chemical synthesis , Carbamates/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , HEK293 Cells , Humans , Lactones/chemical synthesis , Lactones/pharmacology , Morpholines/chemical synthesis , Morpholines/pharmacology , Structure-Activity RelationshipABSTRACT
The bursa of Fabricius (BF) is the central humoral immune organ unique to birds. Here, we isolated a novel bursal pentapeptide I (BPP-I), LGPGP, from BF. BPP-I could play inhibition effect on MCF-7 but not on CEF or Vero cell proliferation in vitro, and enhance antitumor factor p53 protein expression. Also, BPP-I stimulated antibody production in a dose-dependent manner in hybridoma cell. Furthermore, BPP-I could induce various immune responses in mice immunization experiments, including increase antibody production and cytokines IL-4 and IFN-γ level, and induce T-cell immunophenotyping. These results suggest that BPP-I is a potential immunomodulator of antitumor and immunity. The study could provide some novel insights on the probable candidate reagent for the antitumor and immune improvement.
Subject(s)
Adjuvants, Immunologic/pharmacology , Antineoplastic Agents, Hormonal/pharmacology , Bursa of Fabricius/chemistry , Influenza in Birds/prevention & control , Oligopeptides/pharmacology , Adjuvants, Immunologic/chemical synthesis , Adjuvants, Immunologic/isolation & purification , Animals , Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/isolation & purification , Cell Line, Tumor , Cell Proliferation/drug effects , Chickens , Chlorocebus aethiops , Female , Humans , Hybridomas/drug effects , Hybridomas/immunology , Immunization , Influenza A Virus, H9N2 Subtype/drug effects , Influenza A Virus, H9N2 Subtype/immunology , Influenza in Birds/immunology , Influenza in Birds/virology , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Interleukin-4/biosynthesis , Interleukin-4/immunology , Mice , Mice, Inbred BALB C , Oligopeptides/chemical synthesis , Oligopeptides/isolation & purification , T-Lymphocytes/drug effects , T-Lymphocytes/immunologyABSTRACT
The reactions of the breast cancer drug metabolite derivatives of tamoxifen, cis and trans-hydroxytamoxifen, cis-1 and trans-2, with [Cp*Rh(L)(3)](2+) complexes (L = H(2)O or MeOH), in CH(2)Cl(2) and CH(3)OH solvents, initially provided the kinetic η(1)-N complexes, cis-4 (OTf(-), CH(3)OH) and trans-5 (OTf(-), CH(3)OH), which underwent a novel, regioselective, intramolecular N-π rearrangement to give the cis and trans-η(6)-phenol substituted complexes, cis-6 and trans-7, via η(2)-N,O, η(1)-O, and ether aromatic ring η(6) intermediates. Recent density functional theory (DFT) calculations showed a preferred ground state for η(1)-N; η(2)-N,O; η(1)-O; and the η(6) complexes, including the prominent roles of the triflate anion (OTf(-)), and solvent molecules (CH(2)Cl(2) and CH(3)OH), and provided further steric, electronic, and thermodynamic data on the mechanism of the N-π rearrangement. The η(6) complex, cis-6, was shown to be an antagonist for ERα estrogen receptor binding, in a competition experiment with the female hormone, estradiol; therefore, computer docking studies of this biologically active complex at the estrogen receptors, ERα and ERß, also provided information on the binding modes and thermodynamic parameters, while bioassay results provided growth inhibition data on both hormone dependent and independent breast cancer cell lines.
Subject(s)
Antineoplastic Agents, Hormonal , Estrogen Receptor alpha , Estrogen Receptor beta , Organometallic Compounds , Tamoxifen/analogs & derivatives , Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/drug therapy , Cell Line, Tumor , Cell Proliferation/drug effects , Estrogen Receptor alpha/antagonists & inhibitors , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/antagonists & inhibitors , Estrogen Receptor beta/metabolism , Estrogens/metabolism , Female , Humans , Models, Molecular , Organometallic Compounds/chemical synthesis , Organometallic Compounds/pharmacology , Protein Binding , Rhodium/chemistry , Stereoisomerism , Tamoxifen/chemistry , Tamoxifen/pharmacology , ThermodynamicsABSTRACT
It is established that steroid based agents are an example of compounds obtained from natural patterns and are of great importance due to their application in the prevention and treatment of diseases. Selenosteroids are hybrids formed by attaching Se-moiety to a steroid molecule. In these types of hybrids, selenium can be present as selenide or as a part of selenosemicarbazones, isoselenocyanates, selenourea, etc. Attaching a Se-moiety to a biologically active steroid might enhance the biological properties of both fragments. Available literature indicates that these kinds of hybrids demonstrate significant anticancer activity, which renders them interesting in terms of medical use. In this review, we present various methods of synthesis and demonstrate that seleno-steroid compounds are promising molecules for further pharmaceutical application.
Subject(s)
Antineoplastic Agents, Hormonal/chemical synthesis , Chemistry Techniques, Synthetic/methods , Cyanates/chemical synthesis , Organoselenium Compounds/chemical synthesis , Selenium Compounds/chemical synthesis , Steroids/chemical synthesis , Urea/analogs & derivatives , Antineoplastic Agents, Hormonal/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Cyanates/pharmacology , Humans , Inhibitory Concentration 50 , Organoselenium Compounds/pharmacology , Selenium Compounds/pharmacology , Semicarbazones/chemistry , Steroids/pharmacology , Structure-Activity Relationship , Urea/chemical synthesis , Urea/pharmacologyABSTRACT
A crucial event in prostate cancer progression is the transition from a hormone-sensitive to a lethal castration-refractory disease state. The antagonist-to-agonist conversion due to mutation in AR is a critical problem with the current clinically used antiandrogens. We aim to identify novel antiandrogens that remain as a pure antagonist even in the mutated ARs. By synthesizing a series of ionone-based chalcones, we have identified a novel chalcone (17) that is a pan-antagonist of the wild type and the clinically relevant T877A, W741C and H874Y mutated ARs in luciferase reporter assays in PC-3 cells. Further, chalcone 17 demonstrates sub-micromolar to low micromolar antiproliferative activity in LNCaP, MDA-PCa-2b, 22Rv1 and C4-2B prostate cancer cells, all of which express mutated ARs and confer resistance to the current clinically used antiandrogens. The results suggest that chalcone 17 could be a good candidate for further pre-clinical development as a novel antiandrogen for advanced prostate cancer.
Subject(s)
Androgen Antagonists/therapeutic use , Androgen Receptor Antagonists , Antineoplastic Agents, Hormonal/therapeutic use , Chalcones/therapeutic use , Drug Design , Mutation/drug effects , Norisoprenoids/therapeutic use , Androgen Antagonists/chemical synthesis , Androgen Antagonists/pharmacology , Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Chalcones/chemical synthesis , Chalcones/pharmacology , Drug Resistance, Neoplasm/genetics , Drug Screening Assays, Antitumor , Humans , Male , Molecular Structure , Norisoprenoids/chemical synthesis , Norisoprenoids/pharmacology , Receptors, Androgen/genetics , Structure-Activity RelationshipABSTRACT
Leuprolide [DLeu6, NHEt10]GnRH, a potent gonadotropin-releasing hormone (GnRH) agonist, is used in a wide variety of hormone-related diseases like cancer and endometriosis. In this report, the conformational behaviour of Leuprolide and its linear synthetic analogues, namely [Tyr5(OMe), DLeu6, Aze9, NHEt10]GnRH (1) and [Tyr5(OMe), DLeu6, NHEt10]GnRH (2) have been studied in DMSO and H2O solutions by means of 2D nuclear magnetic resonance (NMR) experiments and detailed molecular dynamics (MD) simulations. The aim was to identify the conformational requirements of GnRH analogues for agonistic activity. This approach is of value as no crystallographic data are available for the GnRH receptor (G protein-coupled receptor, GPCR). The NOE data indicate the existence of a ß-turn type I in the 2-5 segments of Leuprolide and its linear analogues in the case of using DMSO-d6 as solvent, whereas a ß-turn type II in the 3-6 segments is indicated using D2O as solvent. The final structures fulfil the conformational requirements that are known, in the literature, to play a significant role in receptor recognition and activation. Finally, the linear analogues (1) and (2) are biologically active when tested against the human breast cancer cell line, MCF-7.
Subject(s)
Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Leuprolide/chemistry , Leuprolide/pharmacology , Antineoplastic Agents, Hormonal/chemical synthesis , Cell Proliferation/drug effects , Dimethyl Sulfoxide/chemistry , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Gonadotropin-Releasing Hormone/agonists , Humans , Leuprolide/analogs & derivatives , Magnetic Resonance Spectroscopy , Models, Molecular , Molecular Conformation , Molecular Dynamics Simulation , Solutions , Structure-Activity Relationship , Tumor Cells, Cultured , Water/chemistryABSTRACT
The synthesis of two separable isomeric testosterone dimers is reported. The dimers are made from testosterone in a 5 step sequence and with 36% overall yield. The key dimerization step was performed using Hoveyda-Grubb's metathesis catalysts on 7alpha-allyltestosterone with 75% yield. The synthesis led to separable isomeric dimers (trans and cis, 2:1). X-ray diffraction crystallography, performed on monocrystal of the minor isomer, confirms the cis geometry of the double bound between the two testosterone units. MTT assays showed that the cis dimer has the highest activity against prostate cancer cell lines. The novel cis dimer is more active than the antiandrogen cyproterone acetate indicating the possible therapeutic value of this molecule.
Subject(s)
Androgen Antagonists/chemistry , Androgen Antagonists/pharmacology , Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Prostatic Neoplasms/drug therapy , Testosterone/analogs & derivatives , Androgen Antagonists/chemical synthesis , Antineoplastic Agents, Hormonal/chemical synthesis , Cell Line, Tumor , Cell Proliferation/drug effects , Crystallography, X-Ray , Drug Screening Assays, Antitumor , Humans , Isomerism , Male , Models, Molecular , Testosterone/chemical synthesis , Testosterone/chemistry , Testosterone/pharmacologyABSTRACT
The present study describes the characterization and evaluation of novel anticancer conjugates, 2,6-diisopropylphenol-docosahexaenoate (PP-DHA), and its analogues including 2,4-diisopropylphenol-docosahexaenoate (DIPP-DHA), 2-isopropylphenol-docosahexaenoate (IPP-DHA), 2-cyclohexanephenol-docosahexaenoate (CHP-DHA) and phenol-docosahexaenoate (P-DHA) on breast cancer cell lines. Representative breast cancer cell lines, based on estrogen alpha receptor (ER) and oncogene Her-2 expression, were used and include MDA-MB-231 (ER-negative, Her-2-negative), MCF-7 (ER-positive, Her-2-negative) AU565 (ER-negative, Her-2-positive) and MDA-MB-361 (ER-positive, Her-2-positive). The PP-DHA conjugate significantly inhibited cell growth and induced cell loss in the breast cancer cell lines similarly; however, this conjugate was not effective against normal mammary epithelial cells. The effect of various conjugates were in PP-DHA>IPP-DHA>DIPP-DHA>CHP-DHA>>P-DHA order. PP-DHA and IPP-DHA conjugates were stable in human and mouse serum. Furthermore, the non-hydrolyzable amide-linked conjugate analogues affected breast cancer cells in a manner similar to that of the ester-linked conjugates. This suggests that ester-linked PP-DHA and IPP-DHA conjugates were stable during treatment to breast cancer cells due to structural hindrance. PP-DHA did not affect PPARalpha or PPARgamma activities but its anticancer effects appear to be mediated in part though the inhibition of histone deacetylase (HDAC) activity. Further experiments are needed to confirm their molecular target and to test the effectiveness of these compounds in an in vivo model for their anticancer properties. In conclusion, these results suggest that the novel PP-DHA and IPP-DHA conjugates and their amide derivatives may be useful for the treatment of breast cancer.
Subject(s)
Antineoplastic Agents, Hormonal/chemistry , Breast Neoplasms/drug therapy , Docosahexaenoic Acids/chemistry , Propofol/chemistry , Animals , Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/therapeutic use , Cell Line, Tumor , Docosahexaenoic Acids/chemical synthesis , Docosahexaenoic Acids/therapeutic use , Estrogen Receptor alpha/metabolism , Female , Histone Deacetylases/chemistry , Histone Deacetylases/metabolism , Humans , Mice , Receptor, ErbB-2/metabolismABSTRACT
A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently.
Subject(s)
Androgen Antagonists , Antineoplastic Agents, Hormonal , Carboxylic Acids , Nitriles/chemical synthesis , Sulfonamides/chemical synthesis , Androgen Antagonists/chemical synthesis , Androgen Antagonists/chemistry , Androgen Antagonists/pharmacology , Animals , Antineoplastic Agents, Hormonal/chemical synthesis , Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Carboxylic Acids/chemical synthesis , Carboxylic Acids/chemistry , Carboxylic Acids/pharmacology , Cell Line, Tumor , Dose-Response Relationship, Drug , Inhibitory Concentration 50 , Male , Mice , Mice, SCID , Molecular Structure , Nitriles/chemistry , Nitriles/therapeutic use , Prostatic Neoplasms/drug therapy , Sulfonamides/chemistry , Sulfonamides/therapeutic use , Thiohydantoins/chemical synthesis , Thiohydantoins/chemistry , Thiohydantoins/pharmacology , Xenograft Model Antitumor AssaysABSTRACT
The syntheses of 21 analogs of 2-methoxyestradiol are presented, including ENMD-1198 which was selected for advancement into Phase 1 clinical trials in oncology. These analogs were evaluated for antiproliferative activity using breast tumor MDA-MB-231 cells, for antiangiogenic activity in HUVEC proliferation assays, and for estrogenic activity in MCF-7 cell proliferation. The most active analogs were evaluated for iv and oral pharmacokinetic properties via cassette dosing in rat and in mice pharmacokinetic models.